AbbVie Inc. $ABBV Stake Trimmed by Raub Brock Capital Management LP

Raub Brock Capital Management LP cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 89,266 shares of the company’s stock after selling 3,319 shares during the quarter. AbbVie accounts for 4.5% of Raub Brock Capital Management LP’s investment portfolio, making the stock its 5th largest position. Raub Brock Capital Management LP’s holdings in AbbVie were worth $20,396,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the second quarter worth $26,000. Chelsea Counsel Co. purchased a new position in AbbVie in the third quarter valued at $26,000. Westend Capital Management LLC acquired a new position in AbbVie during the 4th quarter worth $29,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie during the 3rd quarter worth $31,000. Finally, Caitlin John LLC purchased a new stake in AbbVie during the 3rd quarter worth about $33,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is currently owned by insiders.

AbbVie Stock Performance

NYSE:ABBV opened at $213.12 on Tuesday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a market cap of $376.83 billion, a P/E ratio of 90.30, a P/E/G ratio of 0.73 and a beta of 0.34. The stock has a 50-day simple moving average of $221.93 and a 200-day simple moving average of $224.66.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Royal Bank Of Canada began coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target for the company. Finally, Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.